Drug Development

Pharma company to license novel drug target for HIV treatment

Published in AIDS Weekly, December 19th, 2005

Locus Pharmaceuticals, Inc. announced that it has agreed to license from Cornell Research Foundation a second proprietary crystal structure of the fusion protein gp41, a novel drug target for the treatment of HIV/AIDS.

Locus plans to apply its proprietary computational technologies to this new structure to design small molecule inhibitors of HIV, the AIDS virus.

Min Lu, PhD, associate professor of biochemistry at Weill Medical College of Cornell University, New York City, identified this novel and proprietary domain of gp41, and the 3-dimensional protein structure information forms the basis of the license. Lu has been a key collaborator with Locus...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2005-12-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry